Why the study?
The study aimed to determine the therapeutic maintenance level of methotrexate in rheumatoid arthritis patients in the Moroccan biotherapy registry and identify predictive factors for treatment discontinuation.
What is the therapeutic maintenance level of methotrexate and what are the predictive factors for its discontinuation in patients with rheumatoid arthritis?
Population
224 rheumatoid arthritis patients enrolled in the Moroccan biotherapy registry
Comparison
Predictive factors for discontinuing methotrexate treatment
Design
Cross-sectional study using registry baseline data
Authors
Loading...
MTX maintenance rates and discontinuation predictors in this registry should not change practice; leaves open prospective validation in broader RA populations.
What is the therapeutic maintenance level of methotrexate and what are the predictive factors for its discontinuation in patients with rheumatoid arthritis?
Methotrexate shows satisfactory therapeutic maintenance in rheumatoid arthritis patients, with discontinuation primarily driven by side effects and predicted by the presence of rheumatoid factor and lack of access to education.
Oulkadi et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: